What is the recommended antiviral therapy and supportive care for influenza A infection?

Treatment for Influenza A

Start antiviral treatment immediately with oseltamivir (oral) or zanamivir (inhaled) as soon as influenza A is suspected or confirmed, without waiting for test results, especially in high-risk patients or those with severe disease 1.

Who Should Receive Antiviral Treatment

Mandatory Treatment Groups (Start Immediately):

• Hospitalized patients with suspected or confirmed influenza
• Severe or progressive illness regardless of vaccination status
• High-risk patients:
  • Children <2 years and adults ≥65 years
  • Pregnant women and up to 2 weeks postpartum
  • Chronic medical conditions (cardiac, pulmonary, renal, hepatic, neurologic, hematologic, metabolic disorders including diabetes)
  • Immunocompromised patients
  • Residents of long-term care facilities
  • Morbidly obese (BMI ≥40) 1

Optional Treatment:

• Otherwise healthy outpatients with non-severe illness may be considered for treatment, though benefits are modest 1

First-Line Antiviral Agents

Neuraminidase Inhibitors (NAIs):

Oseltamivir (preferred for most patients):

• Adults: 75 mg orally twice daily for 5 days
• Children ≥1 year: Weight-based dosing:
  • ≤15 kg: 30 mg twice daily

  • 15-23 kg: 45 mg twice daily

  • 23-40 kg: 60 mg twice daily

  • 40 kg: 75 mg twice daily 2

• Dose reduction required for creatinine clearance <30 mL/min 2

Zanamivir (inhaled):

• 10 mg (two inhalations) twice daily for 5 days
• Avoid in patients with underlying airway disease (asthma, COPD) due to bronchospasm risk 1

Peramivir (intravenous):

• Single dose of 600 mg IV for adults
• Reserved for patients unable to take oral or inhaled medications 1

Newer Agent - Baloxavir:

Recent evidence suggests baloxavir may reduce hospital admission risk in high-risk patients and probably reduces symptom duration by approximately 1 day without increasing adverse events 3, 4. However, the 2019 IDSA guidelines predate this evidence and recommend NAIs as first-line 1.

Critical Timing Considerations

Treatment should begin within 48 hours of symptom onset for maximum benefit, but do not withhold treatment beyond 48 hours in:

• Hospitalized patients
• Patients with severe, complicated, or progressive illness
• High-risk patients 1

Duration of Treatment

• Standard duration: 5 days for uncomplicated influenza 1
• Extended duration: Consider longer courses (>5 days) for:
  • Immunocompromised patients with documented persistent viral replication
  • Severe lower respiratory tract disease (pneumonia, ARDS)
  • Patients requiring hospitalization who remain severely ill after 5 days 1

What NOT to Do

Strong Recommendations Against:

Corticosteroids: Do not administer for influenza-associated pneumonia, respiratory failure, or ARDS unless indicated for other reasons (e.g., refractory shock, COPD exacerbation) 1, 3

Antibiotics: Do not routinely prescribe antibiotics in non-severe influenza without evidence of bacterial coinfection 1, 3

Combination NAI therapy: Do not use combinations of neuraminidase inhibitors 1

Higher than approved NAI doses: Do not routinely use higher doses 1

Adamantanes (amantadine, rimantadine): Not recommended due to widespread resistance 2

Managing Bacterial Coinfection

Empirically treat bacterial coinfection with appropriate antibiotics in addition to antivirals when:

• Patients present with severe disease initially (extensive pneumonia, respiratory failure, hypotension)
• Clinical deterioration after initial improvement
• Failure to improve after 3-5 days of antiviral treatment 1

Common bacterial copathogens include Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, and Haemophilus influenzae.

Monitoring and Resistance Testing

Consider NAI resistance testing for:

• Immunocompromised patients with persistent viral replication (>7-10 days) who remain ill during treatment
• Patients who develop influenza while on or immediately after NAI prophylaxis
• Severe influenza patients not improving with treatment and persistent viral replication 1

Common pitfall: Resistance to oseltamivir can emerge during treatment, particularly in immunocompromised patients and children, but remains rare overall (>99% of circulating viruses remain susceptible) 2.

Prophylaxis Considerations

Antiviral chemoprophylaxis is not recommended for routine use but can be considered for:

• Extremely high-risk individuals exposed to confirmed influenza who cannot be vaccinated or when vaccine is unavailable
• Duration: 10 days after household exposure; 7 days after other exposures 2
• Anyone exposed to zoonotic (novel) influenza A viruses 3

Supportive Care

While antivirals are the cornerstone of treatment, ensure:

• Adequate hydration
• Antipyretics for fever (acetaminophen or ibuprofen)
• Rest and symptomatic management
• Close monitoring for complications in high-risk patients

The evidence strongly supports early initiation of neuraminidase inhibitors as the standard of care, with oseltamivir being the most widely used and studied agent 1. The newer agent baloxavir shows promise but requires further real-world validation before replacing NAIs as first-line therapy 3, 4.